<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648399</url>
  </required_header>
  <id_info>
    <org_study_id>wzhao</org_study_id>
    <nct_id>NCT02648399</nct_id>
  </id_info>
  <brief_title>Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study recruit the patients with unilateral papillary thyroid cancer before operation,the
      patients agree to enter the test,and divided into experimental and control group.experimental
      group patients receive the surgery including unilateral thyroid lobectomy and bilateral
      central lymph node dissection.and control group receive the surgery including unilateral
      thyroid lobectomy and unilateral central lymph node dissection.last the investigators compare
      numbers of patient with tumor recurrence and metastasis rate of 5 years,numbers of metastatic
      lymph node,and numbers of participants with adverse events related to treatment between two
      groups in order to evaluate the significance of bilateral lymph node dissection.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>numbers of patients with tumor recurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>numbers of metastatic lymph node</measure>
    <time_frame>1 years</time_frame>
    <description>numbers of metastatic lymph node</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events related to treatment</measure>
    <time_frame>1 years</time_frame>
    <description>numbers of participants with adverse events including recurrent nerve injury，parathyroid injury，hemorrhage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>relations between the lymph metastasis and TNM staging</measure>
    <time_frame>1 years</time_frame>
    <description>Coefficient R (SPSS software for correlation analysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relations between the lymph metastasis and tumor location</measure>
    <time_frame>1 years</time_frame>
    <description>Coefficient R (SPSS software for correlation analysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Thyroid Papillary Carcinoma</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>only unilateral center lymph node dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bilateral center lymph node dissection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery：BCND（bilateral central lymph node dissection）</intervention_name>
    <arm_group_label>experimental group</arm_group_label>
    <other_name>aad another central lymph node dissection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery：UCND（unilateral central lymph node dissection）</intervention_name>
    <arm_group_label>control group</arm_group_label>
    <other_name>only unilateral central lymph node dissection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        according by thyroid carcinoma TNM(tumor,lymph node, metastasis) staging of NCCN (National
        Comprehensive Cancer Network)

        Inclusion Criteria:

          -  1.Unilateral thyroid papillary carcinoma 2.TNM staging: T1~2N0M0

        Exclusion Criteria:

          -  1.Bilateral thyroid papillary carcinoma 2.isthmus thyroid carcinoma 3.TNM staging:
             T3orT4 4.Clinic N1orM1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wenxin zhao, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fujian Medical University Union Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wenxin zhao, doctor</last_name>
    <phone>08613365910359</phone>
    <email>fzhzwx6688@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>shouyi yan, master</last_name>
    <phone>0861598230279</phone>
    <email>yansy1985@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenxin zhao, doctor</last_name>
      <phone>08613365910359</phone>
      <email>fzhzwx6688@163.com</email>
    </contact>
    <contact_backup>
      <last_name>shouyi yan, master</last_name>
      <phone>08615980230279</phone>
      <email>yansy1985@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>January 6, 2016</last_update_submitted>
  <last_update_submitted_qc>January 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fujian Medical University</investigator_affiliation>
    <investigator_full_name>wenxin zhao</investigator_full_name>
    <investigator_title>Director,Vise Head of Acscular and Thyroid Department,Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>thyroid carcinoma</keyword>
  <keyword>center lymph node dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Carcinoma, Papillary</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

